Physician
Defrain, Chad
Defrain, Chad was paid $5.01M by Medicaid between Jan 2018 and Dec 2024, across 197 billing codes. Its largest line is 87633, Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets — 21% of everything it billed.
33Billing provider infoDEFRAIN, CHAD
SPRINGFIELD, IL 62769
SPRINGFIELD, IL 62769
33aNPI1962511931assigned 08/30/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$5.01M
24GClaims626,358
24DCodes billed197
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#10 of 398
Median peer was paid$66K
This provider vs. median76×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 62,678 | $389K | |
| 2019 | 89,660 | $564K | |
| 2020 | 95,753 | $641K | |
| 2021 | 102,617 | $1.04M | |
| 2022 | 97,876 | $941K | |
| 2023 | 89,695 | $767K | |
| 2024incomplete | 88,079 | $674K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 21% | 6,107 | 5,427 | $1.04M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.6% | 9,357 | 7,081 | $280K |
| 80053 | Comprehensive metabolic panel | 3.9% | 37,793 | 23,248 | $196K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.7% | 3,729 | 3,370 | $183K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.6% | 5,382 | 4,416 | $182K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.6% | 62,450 | 35,811 | $179K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 3.2% | 4,159 | 3,657 | $163K |
| 87581 | 2.9% | 6,640 | 5,924 | $146K | |
| 87486 | 2.9% | 6,636 | 5,921 | $146K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.7% | 33,436 | 16,432 | $137K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 2.3% | 5,446 | 4,992 | $117K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 2.3% | 5,416 | 4,968 | $116K |
185 more codes
| 82805 | 2.0% | 3,768 | $99K | |
| 82948 | 1.7% | 32,097 | $86K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.7% | 2,136 | $84K |
| 83735 | 1.6% | 23,404 | $80K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.6% | 15,378 | $78K |
| 87040 | 1.5% | 7,009 | $75K | |
| 82803 | 1.3% | 6,716 | $67K | |
| 84443 | Thyroid stimulating hormone (TSH) | 1.3% | 7,956 | $64K |
| 87480 | 1.1% | 4,775 | $55K | |
| 82330 | 1.1% | 6,494 | $54K | |
| 87510 | 1.1% | 4,644 | $53K | |
| 84484 | 1.0% | 11,572 | $51K | |
| 87641 | <1% | 2,238 | $49K | |
| 87507 | <1% | 284 | $48K | |
| 83880 | <1% | 4,434 | $47K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 1,245 | $44K |
| 83605 | <1% | 7,941 | $43K | |
| 85027 | <1% | 14,161 | $41K | |
| 88307 | <1% | 650 | $40K | |
| 83690 | <1% | 11,097 | $38K | |
| 87660 | <1% | 4,925 | $37K | |
| 84702 | <1% | 7,502 | $33K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,235 | $33K |
| 87653 | <1% | 1,462 | $32K | |
| 87797 | <1% | 2,603 | $32K | |
| 86901 | <1% | 11,684 | $29K | |
| 81001 | <1% | 20,970 | $28K | |
| 85610 | <1% | 13,892 | $28K | |
| 87186 | <1% | 4,648 | $27K | |
| 86850 | <1% | 9,345 | $27K | |
| 85730 | <1% | 7,259 | $25K | |
| 84100 | <1% | 11,334 | $24K | |
| 86900 | <1% | 11,689 | $22K | |
| 80202 | <1% | 2,949 | $19K | |
| 80076 | <1% | 4,960 | $17K | |
| 86803 | <1% | 2,079 | $17K | |
| 87430 | <1% | 2,161 | $17K | |
| 85379 | <1% | 4,100 | $16K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 670 | $15K |
| 81025 | <1% | 6,829 | $15K | |
| 82248 | <1% | 6,568 | $13K | |
| 85007 | <1% | 7,451 | $13K | |
| 82247 | <1% | 6,030 | $12K | |
| 80061 | Lipid panel | <1% | 3,430 | $12K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 810 | $11K |
| 86140 | <1% | 4,485 | $10K | |
| 87340 | <1% | 1,622 | $10K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,222 | $10K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,150 | $9K |
| 82550 | <1% | 3,033 | $9K | |
| 87070 | <1% | 2,889 | $9K | |
| 83615 | <1% | 3,022 | $9K | |
| 87205 | <1% | 4,173 | $9K | |
| 84439 | <1% | 1,986 | $9K | |
| 80074 | <1% | 440 | $8K | |
| 82728 | <1% | 2,017 | $8K | |
| 82565 | <1% | 3,788 | $8K | |
| 87081 | <1% | 2,733 | $7K | |
| 85014 | <1% | 6,204 | $7K | |
| 84295 | <1% | 3,542 | $7K | |
| 86880 | <1% | 2,435 | $7K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 171 | $7K |
| 84132 | <1% | 3,605 | $6K | |
| 82607 | <1% | 1,065 | $6K | |
| 86780 | <1% | 860 | $6K | |
| 82140 | <1% | 1,402 | $6K | |
| 80069 | <1% | 1,414 | $6K | |
| 85520 | <1% | 1,193 | $6K | |
| 86592 | <1% | 3,031 | $6K | |
| 87400 | <1% | 694 | $6K | |
| 83550 | <1% | 1,431 | $6K | |
| 84460 | <1% | 2,434 | $5K | |
| 87088 | <1% | 959 | $5K | |
| 84450 | <1% | 2,403 | $5K | |
| 83540 | <1% | 1,663 | $5K | |
| 84550 | <1% | 2,542 | $5K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 243 | $5K |
| 86762 | <1% | 1,119 | $5K | |
| 82150 | <1% | 1,004 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 555 | $4K |
| 85046 | <1% | 1,704 | $4K | |
| 85384 | <1% | 1,256 | $4K | |
| 82570 | <1% | 1,920 | $4K | |
| 87184 | <1% | 907 | $4K | |
| 83021 | <1% | 700 | $4K | |
| 86870 | <1% | 502 | $4K | |
| 80081 | <1% | 113 | $4K | |
| 87075 | <1% | 525 | $4K | |
| 80051 | <1% | 1,246 | $4K | |
| 82553 | <1% | 783 | $4K | |
| 85652 | <1% | 2,717 | $3K | |
| 82784 | <1% | 539 | $3K | |
| 87015 | <1% | 825 | $3K | |
| 87420 | <1% | 413 | $3K | |
| 82010 | <1% | 1,342 | $3K | |
| 86922 | <1% | 283 | $3K | |
| 86038 | <1% | 390 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 201 | $3K |
| 85018 | <1% | 2,645 | $3K | |
| 82746 | <1% | 467 | $3K | |
| 86003 | <1% | 117 | $3K | |
| 87147 | <1% | 1,204 | $3K | |
| 87493 | <1% | 150 | $2K | |
| 82310 | <1% | 1,359 | $2K | |
| 87449 | <1% | 305 | $2K | |
| 87077 | <1% | 1,707 | $2K | |
| 83970 | <1% | 139 | $2K | |
| 84146 | <1% | 318 | $2K | |
| 86920 | <1% | 417 | $2K | |
| 86225 | <1% | 348 | $2K | |
| 80306 | <1% | 351 | $2K | |
| 83516 | <1% | 321 | $2K | |
| 89051 | <1% | 621 | $2K | |
| 84520 | <1% | 1,274 | $2K | |
| 82533 | <1% | 237 | $2K | |
| 84156 | <1% | 1,636 | $2K | |
| 82105 | <1% | 199 | $2K | |
| 81003 | <1% | 1,316 | $1K | |
| 86787 | <1% | 213 | $1K | |
| 86706 | <1% | 207 | $1K | |
| 87102 | <1% | 374 | $1K | |
| 88304 | <1% | 72 | $1K | |
| 83001 | <1% | 142 | $1K | |
| 83655 | <1% | 204 | $1K | |
| 87807 | <1% | 239 | $1K | |
| 84703 | <1% | 324 | $1K | |
| 86480 | <1% | 41 | $1K | |
| 84478 | <1% | 501 | $1K | |
| 84466 | <1% | 225 | $924.13 | |
| 84481 | <1% | 194 | $910.82 | |
| 84403 | <1% | 72 | $907.28 | |
| 86885 | <1% | 282 | $881.45 | |
| 87181 | <1% | 103 | $881.38 | |
| 84300 | <1% | 406 | $843.76 | |
| 87324 | <1% | 107 | $820.11 | |
| 86704 | <1% | 105 | $808.55 | |
| 85347 | <1% | 241 | $796.34 | |
| 82785 | <1% | 160 | $698.32 | |
| 87899 | <1% | 78 | $676.89 | |
| 87206 | <1% | 251 | $600.48 | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 67 | $563.61 |
| 81329 | <1% | 18 | $537.60 | |
| 85049 | <1% | 577 | $527.78 | |
| 86147 | <1% | 23 | $489.95 | |
| 87116 | <1% | 69 | $479.70 | |
| 88141 | <1% | 29 | $453.38 | |
| 82945 | <1% | 280 | $437.36 | |
| 87522 | Neg quan hep c or qual rna | <1% | 16 | $419.25 |
| 83930 | <1% | 145 | $414.74 | |
| 84157 | <1% | 342 | $405.65 | |
| 82375 | <1% | 83 | $341.50 | |
| 84075 | <1% | 182 | $329.90 | |
| 80164 | <1% | 58 | $269.83 | |
| 87254 | <1% | 31 | $252.80 | |
| 87176 | <1% | 60 | $250.25 | |
| 86308 | <1% | 101 | $240.00 | |
| 82977 | <1% | 96 | $229.50 | |
| 83050 | <1% | 78 | $214.26 | |
| 84145 | <1% | 52 | $212.29 | |
| 83935 | <1% | 84 | $207.37 | |
| 87450 | <1% | 31 | $201.84 | |
| 84155 | <1% | 157 | $182.02 | |
| 82043 | <1% | 86 | $166.03 | |
| 82947 | <1% | 140 | $145.21 | |
| 84402 | <1% | 15 | $134.75 | |
| 80177 | <1% | 28 | $134.64 | |
| 86645 | <1% | 12 | $109.44 | |
| 82950 | <1% | 47 | $107.18 | |
| 84305 | <1% | 12 | $90.48 | |
| 83002 | <1% | 15 | $80.60 | |
| 85461 | <1% | 26 | $75.88 | |
| 86431 | <1% | 25 | $72.68 | |
| 85613 | <1% | 19 | $66.69 | |
| 84133 | <1% | 34 | $60.90 | |
| 82042 | <1% | 24 | $55.20 | |
| 84134 | <1% | 12 | $52.56 | |
| 88342 | <1% | 12 | $50.85 | |
| 85660 | <1% | 19 | $44.27 | |
| 85060 | <1% | 12 | $40.50 | |
| 85670 | <1% | 15 | $37.28 | |
| 85460 | <1% | 13 | $32.52 | |
| 87185 | <1% | 13 | $32.11 | |
| 82272 | <1% | 15 | $19.05 | |
| 86923 | 0% | 303 | $0.00 | |
| 87150 | 0% | 180 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.